Browsing Tag
FDA Type B meeting
2 posts
MoonLake Immunotherapeutics says FDA supports existing clinical data for sonelokimab, announces investor day amid strong market reaction
Find out how MoonLake Immunotherapeutics gained FDA support for its sonelokimab data and why investors are watching its 2026 regulatory path closely.
ProKidney (NASDAQ: PROK) stock surges over 22% after Phase 2 REGEN-007 trial shows strong kidney function stabilization
Find out why ProKidney stock soared 22% after new Phase 2 data on rilparencel in chronic kidney disease patients. Analysts see potential FDA fast-track.